22,615 Pfizer Inc. $PFE Shares Bought by Provenance Wealth Advisors LLC

Provenance Wealth Advisors LLC increased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 132.4% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 39,699 shares of the biopharmaceutical company’s stock after acquiring an additional 22,615 shares during the quarter. Provenance Wealth Advisors LLC’s holdings in Pfizer were worth $1,132,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. TOWER TRUST & INVESTMENT Co increased its holdings in Pfizer by 1.9% during the third quarter. TOWER TRUST & INVESTMENT Co now owns 19,322 shares of the biopharmaceutical company’s stock worth $551,000 after buying an additional 357 shares during the last quarter. Angeles Wealth Management LLC raised its position in Pfizer by 2.2% in the second quarter. Angeles Wealth Management LLC now owns 17,009 shares of the biopharmaceutical company’s stock worth $410,000 after acquiring an additional 358 shares during the period. Manchester Financial Inc. boosted its stake in Pfizer by 2.9% in the second quarter. Manchester Financial Inc. now owns 13,168 shares of the biopharmaceutical company’s stock valued at $317,000 after acquiring an additional 365 shares during the last quarter. Signature Equity Partners LLC boosted its stake in Pfizer by 22.9% in the third quarter. Signature Equity Partners LLC now owns 2,067 shares of the biopharmaceutical company’s stock valued at $59,000 after acquiring an additional 385 shares during the last quarter. Finally, Delta Financial Advisors LLC grew its position in shares of Pfizer by 1.6% during the 1st quarter. Delta Financial Advisors LLC now owns 25,266 shares of the biopharmaceutical company’s stock valued at $709,000 after acquiring an additional 398 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on PFE. Weiss Ratings upgraded shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, August 31st. Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a research note on Saturday, October 10th. JPMorgan Chase & Co. upped their price objective on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research note on Friday, October 9th. Guggenheim reissued a “buy” rating on shares of Pfizer in a report on Tuesday, October 13th. Finally, BMO Capital Markets decreased their target price on Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a research report on Monday, July 13th. Five research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $29.81.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer beat third-quarter estimates, reporting adjusted EPS of $0.87 and revenue of $16.58 billion. It raised its 2026 revenue outlook to $62–$64 billion and adjusted EPS forecast to $2.95–$3.05, citing execution and cost savings. Reuters article
• Positive Sentiment: Growth in newer and acquired medicines is helping offset pandemic-product declines: these products grew 32% operationally in Q3, while non-COVID products overall grew 7%. This supports Pfizer’s effort to build growth beyond COVID sales. The Motley Fool article
• Positive Sentiment: Scotiabank raised its price target to $35 and maintained a “sector outperform” rating, signaling further potential upside. Ticker Report article
• Neutral Sentiment: Pfizer named Cecile Guegan permanent CFO after she served in the interim role. The appointment provides leadership continuity, though its near-term financial impact is unclear. Business Wire announcement
• Negative Sentiment: COVID-related product sales continued to decline, and revenue was slightly lower year over year. UBS and Citi raised their targets to $30 and RBC to $28, but each retained a neutral or sector-perform rating—targets below the recent share price that may temper expectations. UBS rating

Pfizer Price Performance

Shares of NYSE:PFE opened at $30.79 on Thursday. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71. The firm has a market capitalization of $175.52 billion, a PE ratio of 43.99, a P/E/G ratio of 2.04 and a beta of 0.31. Pfizer Inc. has a twelve month low of $23.62 and a twelve month high of $31.06. The company has a 50-day moving average price of $28.69 and a two-hundred day moving average price of $26.86.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, November 3rd. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.74 by $0.13. Pfizer had a net margin of 6.34% and a return on equity of 19.98%. The company had revenue of $16.58 billion for the quarter, compared to analyst estimates of $15.85 billion. During the same quarter in the previous year, the firm posted $0.87 earnings per share. The company’s quarterly revenue was down .4% compared to the same quarter last year. Equities analysts forecast that Pfizer Inc. will post 2.94 EPS for the current year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 7th. Investors of record on Friday, November 6th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 5.6%. The ex-dividend date is Friday, November 6th. Pfizer’s payout ratio is currently 226.32%.

Pfizer Profile

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.